Edelman continued, SherpaPak provides best-in-class donor organ management solutions for safe and reliable preservation and transport of donor hearts and kidneys. In November 2016, we engaged in an exclusive distribution agreement with Pacific West Medical Sales. We are adding distribution capability to our growing channel and look to have additional announcements in the near future. The Paragonix SherpaPak devices for kidney and heart preservation are an important step in improving donor organ transportation. http://nicesavannahyoung.strategygolfcentral.com/2016/09/21/they-then-begin-feeding-on-the-body-stealing-nutrition-in-an-attempt-to-grow-and-thus-become-cancerousWe believe that improving the utilization of donated organs is critical to patients in end-stage organ failure who are desperate for this precious commodity. Previous Announcements Paragonix previously announced November 9, 2016 an exclusive distribution agreement with Pacific West Medical Sales for Paragonix SherpaPak Cardiac and Kidney Transport Systems in California Paragonix previously announced June 29, 2016 a Product Supply Agreement with Waters Medical Systems LLC, for Waters IGL and Celsior Cold Storage Solutions for Use With the SherpaPak Kidney Transport System and SherpaPak Cardiac Transport System Paragonix and Essential Pharmaceuticals LLC previously announced June 28, 2016, a Product Supply Agreement for Custodiol HTK Organ Preservation Solution for Use With the SherpaPak Cardiac Transport System and SherpaPak Kidney Transport System Paragonix previously announced June 6, 2016, Presentation of the SherpaPak Cardiac Transport System during the 2016 American Transplant Congress June 11 – 15, 2016 in Boston, MA Paragonix previously announced on July 23, 2015, Publication of Innovative Cold Storage Of Donor Organs Using The Paragonix SherpaPak Devices”1 Paragonix previously announced on February 9, 2015, Innovative Tracking Technology For Thanks Real-Time, National Location Tracking of Donor Organs Paragonix previously announced on December 2, 2014, clearance of two 510(k) Premarket Notifications by the article source US Food and Drug Administration, allowing the Paragonix Sherpa Pak Transport Systems to be combined and distributed with any FDA-cleared, commercially-available preservation solution Paragonix previously announced on Nov 17, 2014, Receipt of ISO 13485:2003 Certification for the Paragonix Sherpa Organ Storage and Transport Systems Paragonix previously announced on Nov 3, 2014, filing of two 510(k) FDA Pre-Market Notifications to combine the Paragonix Sherpa Pak Cardiac and Kidney Transport Systems with any effective organ preservation solution currently marketed under 510(k) Pre-market Clearance Paragonix previously announced on Oct 27, Ta 2014, joining of David DAlessandro, MD, as Medical Director for Paragonix About Bio Instruments, LLC Bio Instruments, LLC was ta founded in 1978. The Company represents the upper Midwestspecializing in products for Cardiac, Vascular, and Thoracic procedures. About the Paragonix SherpaPak and SherpaPerfusion Cardiac Transport System Currently, the availability of cardiac transplantation is governed by the ischemic time, that being, the elapsed time from heart donation to recipient implantation. According to The International Society Of Heart and Lung Transplantation (ISHLT) guidelines2 for the care of heart transplant recipients, the projected ischemic time should not exceed 4 hours3,4, limiting the distance available to transport a donor heart. Paragonix SherpaPak Cardiac Transport System is fully disposable, eliminating problems associated with maintenance, device transport and contamination.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/paragonix-technologies-inc-bio-instruments-110000353.html